Merck’s Covid Pill Narrowly Gets Backing From FDA Advisers
- Thin vote margin highlights safety concerns about treatment
- Decision comes as scientists race to study new omicron variant
This article is for subscribers only.
Merck & Co.’s Covid-19 pill narrowly gained a key recommendation from advisers to U.S. regulators, after a lengthy debate about the safety of the potential game-changing treatment.
The Food and Drug Administration’s advisory committee voted 13-10 to back Merck’s antiviral drug molnupiravir, saying that while there were safety concerns about the pill, its potential benefits outweigh the risks.